Gene therapy: Basic concepts and recent advances

Critical Reviews in Eukaryotic Gene Expression

Volumn 6, Issue 1, 1996, Pages 29-57

  Sokol, Deborah L ^a   Gewirtz, Alan M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

adenovirus; antisense; gene marking; liposomes; retroviruses; review

Indexed keywords

ADENOVIRUS; ANIMAL CELL; BONE MARROW CELL; CHEMOSENSITIVITY; GENE THERAPY; GENETIC DISORDER; GENETIC ENGINEERING; IMMUNOPHENOTYPING; MARKER GENE; NONHUMAN; PRIORITY JOURNAL; RECOMBINANT DNA TECHNOLOGY; RETROVIRUS; REVIEW;

ADENOVIRIDAE; ANIMALIA; UNIDENTIFIED RETROVIRUS;

EID: 0029962408     PISSN: 10454403     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevEukarGeneExpr.v6.i1.30     Document Type: Review

References (218)

1. Agrawal S, Temsamani J, Tang J (1991): Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc Natl Acad Sci USA 88:7595-7599.
2. Akhtar S, Kole R, Juliano R (1991): Stability of modified antisense oligodeoxynucleotides in cellular extracts and sera. Life Sci 49:1793-1801.
3. Akli S, Caillaud C, Vigne E, Stratfored-Perricaudet L, Poenaru L, Perricaudet M, Kahn A, Peschanski M (1993): Transfer of a foreign gene into the brain using adenovirus vectors. Nature Genetics 3:224-228.
4. Anderson W (1992): Human gene therapy. Science 256:808-813.
5. Avery T, MacLeod C, MacCarty M (1944): Studies on the chemical nature of the substance inducing transformation of pneumoccal types. J Exp Med 79:137-157.
6. Barr E, Carroll J, Kalynych A, Tripathy S, Kozarsky K, Wilson J, Leiden J (1994): Efficient catheter-mediated gene transfer into the heart using replication-defective adenovirus. Gene Therapy 1:51-58.
7. Bassin R, Tuttle N, Fischinger P (1971): Rapid cell culture assay technique for murine leukemia viruses. Nature 229:564-566.
8. Batchu B, Kotin R, Hermonat P (1994): The regulatory rep protein of adeno associated virus binds to sequences within the c-H ras promoter. Cancer Lett 86:23-31.
9. Bayever E, Iversen P (1994): Oligonucleotides in the treatment of leukemia. Hematol Oncol 12:9-14.
10. Beckner K (1988): Development of adenovirus vectors for the expression of heterologous genes. BioTechniques 6:616-629.
11. Benbernou N, Matsiota-Bernard P, Guenounou M (1993): Antisense oligodeoxynucleotides to interleukin-4 regulates IgE and IgG2a production by spleen cells from Nippostrongylus brasiliensis-infected rats. Eur J Immunol 23:659-663.
12. Berencsi K, Uri A, Valyi-Nagy T, Valyi-Nagy I, Meignier B, Peretz F, Rando R, Plotkin S, Gonczol E (1994): Early region 3-replacement adenovirus recombinants are less pathogenic in cotton rats and mice than early region 3-deleted viruses. Lab Invest 71:350-358.
13. Berns K (1990): Parvovirus replication. Microbiol Rev 54:316-329.
14. Berns K, Linden R (1995): The cryptic lifestyle of adeno-associated virus. Bioassays 17:237-245.
15. Black L, Degeorge J, Cavagnaro J, Jordan A, Ahn C (1993): Regulatory considerations for evaluating the pharmacology and toxicology of antisense drugs. Antisense Res Dev 3:399-404.
16. Boiziau C, Kurfurst R, Cazanave C, Roig V, Thoung N, Toulme J (1991): Inhibition of translation initiation by antisense oligonucleotides via an RNAase H independent mechanism. Nucl Acids Res 19:1113-1119.
17. Bolensky R, LeFebvre R, Berns K (1988): Sequence and symmetry requirements within the internal palindrome sequences of the adeno-associated virus terminal repeat. Virology 166:316-327.
18. Brawerman G (1990): Mechanisms of mRNA decay. TIBTECH 8:171-174.
19. Brenner M (1991a): Autologous bone marrow transplant for children with acute myelogenous leukemia in first complete remission: use of marker genes to investigate the biology of marrow reconstitution and the mechanisms of relapse. Hum Gene Ther 2:137-159.
20. Brenner M (1991b): A phase I trial of high-dose carboplatin and etoposide with autologous marrow support for treatment of stage D neuroblastoma in first remission: use of marker genes to investigate the biology of marrow reconstitution and the mechanism of relapse. Hum Gene Ther 2:257-272.
21. Brown M, Goldstein J, Havel R, Steinberg D (1994): Gene therapy for cholesterol. Lett Nature Genetics 7:349-350.
22. Bryson H, Sorkin E (1994): Dornase Alfa. A review of its pharmacological properties and therapeutic potential in cystic fibrosis. Drugs 48:894-906.
23. Cameron F, Jennings P (1989): Specific gene suppression by engineered ribozymes in monkey cells. Proc Natl Acad Sci USA 86:9139-9143.
24. Carter B (1990): in "Handbook of Parvoviruses," Tijssen, P (ed): Boca Raton, FL: CRC Press vol 2, pp 247-284.
25. Castannoto, D, Rossi J, Deshler J (1992): Biological and functional aspects of catalytic RNAs. Crit Rev Euk Gene Exp 2:331-357.
26. Cazenave C, Stein C, Loreau N, Thoung N, Neckers L, Subasinghe C, Helene C, Cohen J, Toulme J (1989): Comparative inhibition of rabbit globin mRNA translation by modified antisense oligodeoxynucleotides. NAR 17:4255-4273.
27. Chaudhary D, Roninson I (1991): Expression and activation of P-glycoprotein, a multidrug efflux pump in human hematopoietic stem cells. Cell 66:85-94.
28. Chejanovsky N, Loyter A (1985): Fusion between Sendai virus envelopes and biological membranes, The use of fluorescent probes for quantitative estimates of virus-membrane fusion. J Biol Chem 260:7911-7919.
29. Chejanovsky N, Zakai N, Amselem S, Barenholz Y, Loyter A (1986): Membrane vesicles containing the Sendai virus binding glycoprotein, but not the viral fusion protein, fuse with phosphatidylserine liposomes at low pH. Biochemistry 25:4810-4817.
30. Chiang M, Chan H, Zounes M, Freier S, Lima W, Bennett C (1991): Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms. J Biol Chem 266:18162-18171.
31. Chin D, Green G, Zon J, Szoka F, Straubinger R (1990): Rapid nuclear accumulation of injected oligodeoxyribonucleotides. New Biol 2:1091-1110.
32. Chowrira B, Berzal-Herranz A, Burke J (1993): Ionic requirements for RNA binding, cleavage, and ligation by the hairpin ribozyme. Biochemistry 32:1088-1095.
33. Chu C, Dijkstra M, Lai Z, Hong K, Szoka C (1990): Efficiency of cytoplasmic delivery by pH sensitive liposomes to cells in culture. Pharm Res 7:824-834.
34. Cornetta K, Morgan R, Gillio A, Sturm S, Baltrucki L, O'Reilly R, Anderson W (1991): No retroviremia in long-term follow-up of monkeys exposed to a murine amphotropic retrovirus. Hum Gene Ther 2:215-219.
35. Cornish K, Iversen P, Smith L, Arneson M, Baever E (1993): Cardiovascular effects of a phosphorothioate oligonucleotide with sequence antisense to p53 in the conscious rhesus monkey. Pharmacol Commun 3:239-247.
36. Cotten M, Wagner E, Zatlovkal K, Phillips S, Curiel D, Birnstiel M (1992): High-efficiency receptor-mediated delivery of small and large (48 kilobase) gene constructs using the endosome disruption activity of defective or chemically inactivated adenovirus particles. Proc Natl Acad Sci USA 89:6094-6098.
37. Crooke R (1991): In vitro toxicology and pharmacokinetics of antisense oligonucleotides. Anticancer Drug Des 6:609-646.
38. Crooke S (1994): Advances in oligonucleotide therapeutics. Experimental Biology Meeting, American Society for Pharmacology and Experimental Therapeutics, Anaheim, CA, April 24-28, 1994. Abstract.
39. Culver K, Ram Z, Wallbridge S, Ishii H, Oldfield E, Blaese R (1992): In vivo gene transfer with retroviral vector producer cells for treatment of experimental brain tumors. Science 256:1550-1552.
40. Curiel D, Agarway S, Wagner E, Cotten M (1991): Adenovirus enhancement of transferrin polylysine-mediated gene delivery. Proc Natl Acad Sci USA 88:8850-8854.
41. Curiel D, Wagner E, Cotten M, Birnstiel M, Agarway S, Li C, Loechel S, Hu P (1992): High-efficiency gene transfer mediated by adenovirus coupled to DNA-polylysine complexes. Hum Gene Ther 3:147-154.
42. Danos O, Mulligan R (1988): Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. Proc Natl Acad Sci USA 85:6460-6464.
43. Davis H, Michel M, Whalen R (1993): DNA-based immunization induces continuous secretion of hepatitis B suface antigen and high levels of circulating antibody. Hum Mol Genet 2:1847-1851.
44. Defer C, Belin M, Caillet-Boudin M, Boulanger P (1990): Human adenovirus host cell interactions: comparative study with members of subgroups B and C. J Virol 64:3661-3673.
45. deFiebre C, Bryant S, Notabartolo D, Wu P, Meyer E (1993): Fusogenic properties of Sendai virosome envelopes in rat brain preparations. Neurochem Res 18:1089-1094.
46. deFiebre C, Wu P, Notabartolo D, Millard W, Meyer E (1994): Differential Adeno-associated virus vector driven expression of a neuropeptide Y gene in primary rat brain astroglial cultures after transfection with Sendai virosomes versus lipofectin. Neurochem Res 19:643-648.
47. Deisseroth A (1991): Autologous bone marrow transplantation for chronic myelogenous leukemia in which retroviral markers are used to discriminate between relapse which arises from systemic disease remaining after preparative therapy versus relapse due to residual leukemic cells in autologous marrow: a pilot trial. Hum Gene Ther 2:359-376.
48. Deisseroth A, Hanania E, Fu S, Champlin R, Claxton D, Berenson R, Heimfeld S, Giles R, Kavanagh J (1995): Strategies for modification of the hematopoietic stem cell. In "Educational Book: American Society of Clinical Oncology." Los Angeles, CA: Bostrom Corp. pp 272-275.
49. Denhardt D (1992): Mechanism of action of antisense RNA, sometime inhibition of transcription processing, transport, or translation (review). Annal New York Acad Sci 660:70-76.
50. Dixit M, Webb M, Smart W, Ohi S (1991): Construction and expression of a recombinant adeno-associated virus that harbors a human B-globin encoding cDNA. Gene 104:253-257.
51. + cells. J Cell Biochem 16F:46.
52. Dunckley M, Wells D, Walsh F, Dickson G (1993): Direct retroviral-mediated transfer of a dystrophin minigene into mdx mouse muscle in vivo. Hum Mol Gene 2:717-723.
53. Earl R, Hunneyball I, Billett E, Mayer R (1987): Evaluation of reconstituted Sendai virus as intraarticular drug vectors: effects on normal and experimentally arthritic knee joints. J Pharm. Pharmacol 40:166-170.
54. Eckstein F (1985): Nucleoside phosphorothioates. Ann Rev Biochem 54:367-402.
55. Ellens J, Bentz J, Szoka F (1984): pH-induced destabilization of phosphatidylethanolamine containing liposomes: role of bilayer contact. Biochemistry 23:1532-1538.
56. Epstein S (1991): Regulatory concerns in human gene therapy. Hum Gene Ther 2:243-249.
57. Fedor M, Uhlenbeck O (1990): Substrate sequence effects on "hammerhead" RNA catalytic efficiency. Proc Natl Acad Sci USA 87:1668-1672.
58. Feigner P, Gadek T, Hoolm M, Roman R, Chan H, Wenz M, Northrop G, Ringold M, Danielsen M (1987): Lipofection: a highly efficient lipid-mediated DNA transfection procedure. Proc Natl Acad Sci USA 84:7413-7417.
59. Feigner P, Ringold G (1989): Cationic liposome-mediated transfection. Nature 337:387-388.
60. Feigner P (1990): Particulate systems and polymers for in vitro and in vivo delivery of polynucleotides. Advanced Drug Del 5:163-187.
61. Fisher T, Terhorst T, Cao X, Wagner R (1993): Intracellular distribution and metabolism of fluorescently labelled unmodified and modified oligodeoxynucleotides microinjected into mammalian cells. NAR 21:3857-3865.
62. Flotte T, Afiore S, Conrad C, McGrath S, Solow R, Oko H, Zeitlin P, Guggino W, Carter B (1993): Stable in vivo expression of the cystic fibrosis transmembrane regulator with an adeno associated virus vector. Proc Natl Acad Sci USA 90:10613-10617.
63. Forster A, Symons H (1987): Self-cleavage of plus and minus RNAs of a virusoid and a structural model for the active sites. Cell 49:211-220.
64. Freeman S, Abboud C, Whartonby K, Packman C, Koeplin D, Moolten F, Abraham G (1993): The "bystander" effect: tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 53:5274-5283.
65. Friedmann T (1989): Progress toward human gene therapy. Science 244:1275-1281.
66. Furuichi Y, LaFiandra A, Shatkin A (1977): 5′-Terminal structure and mRNA stability. Nature 266: 235-239.
67. Gabizon A, Paphadopoulos D (1988): Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci USA 85:6949-6953.
68. Gabizon A, Price D, Huberty J, Bresailer R, Papahadjopoulos D (1990): Effect of liposome composition and other factors on the targeting of liposomes to experimental tumors: biodistribution and imaging studies. Cancer Res 50:6371-6378.
69. Galbraith W, Hobson W, Giclas P, Schechter P, Agrawal S (1994): Complement activation and hemodynamic changes following intravenous administration of phosphorothioate olignucleotides in the monkey. Antisense Res Dev 4:201-207.
70. Gansbacher B, Bannerji R, Daniels B, Zier K, Cronin K, Gilboa E (1990): Retroviral vector-mediated gamma interferon gene transfer into tumor cells generates potent and long-lasting antitumor immunity. Cancer Res 50:7820-7825.
71. Gansbacher B (1995): Genetically engineered cancer vaccines for renal carcinoma and melanoma. In "Educational Book: American Society of Clinical Oncology". Los Angeles, CA: Bostrom Corp. p. 276-280.
72. Geller A. Breakefield X (1988): A defective HSV-1 vector expresses Escherichia coli β-galactosidase in cultured peripheral neurons. Science 241:1667-1669.
73. Ginsberg H, Lundholm-Beauchamp U, Horswood R, Pernis B, Wold W, Chanock R (1989): Role of early region 3 (E3) in pathogenesis of adenovirus disease. Proc Natl Acad Sci USA 86:3823-3827.
74. Ginsberg H, Sehgal P, Redington M, Kilian P, Chanock R, Prince G (1991): A mouse model for investigating the molecular pathogenesis of adenovirus pneumonia. Proc Natl Acad Sci USA 88:1651-1655.
75. Gitman A, Loyter A (1984): Construction of fusogenic vesicles bearing specific antibodies: targeting of reconstituted Sendai virus envelopes towards neuraminidase-treated human erythrocytes. J Biol Chem 259:9813-9820.
76. Gitman A, Graessmann A, Loyter A (1985): Targeting of loaded Sendai virus envelopes by covalently attached insulin molecules to virus receptor-depleted cells: fusion-mediated microinjection of ricin A and simian virus 40 DNA. Proc Natl Acad Sci USA 82:7309-7313.
77. Graham F, Smiley J, Russsell W, Nairn R (1977): Characteristics of a human cell line transformed by human adenovirus type 5. J Gen Virol 36:59-72.
78. Graham F, Prevec L (1992): Adenovirus-based expression vectors and recombinant vaccines. In Ellis R (ed): Vaccines: new approaches to immunological problems. Boston: Butterworth-Heinerous, pp 363-390.
79. Greber U, Willetts M, Webster P, Helenius A (1993): Stepwise dismantling of adenovirus 2 during entry into cells. Cell 75:477-486.
80. Grosshans C, Cech T (1989): Metal ion requirements for sequence-specific endoribonuclease activity of the tetrahymena ribozyme. Biochem 28:6888-6894.
81. Grossman M, Raper S, Wilson J (1992): Transplantation of genetically modified autologous hepatocytes into non-human primates. Feasibility and short-term toxicity. Hum Gene Ther 3:501-510.
82. Grossman M, Raper S, Kozarsky K, Stein E, Engelhart J, Muyller D, Lupien P, Wilson J (1994): Successful ex vivo gene therapy directed to the liver in a patient with familial hyperchlosterolaemia. Nature Genetics 6:335-341.
83. Hermonat P, Lablow M, Wright R, Berns K, Muzyczkan (1984): Genetics of adeno associated virus isolation and preliminary characterization of adeno associated virus type 2 mutants. J Virol 5:329-333.
84. Hermonat P, Muzyxzka N (1984): Use of adeno-associated virus as a mammalian DNA cloning vector: transduction of neomycin resistance into mammalian tissue culture cells. Proc Natl Acad Sci USA 81:6466-6470.
85. Hermonat P (1989): The adeno associated virus rep 78 gene inhibits cellular transformation induced by bovine papillomavirus. Virology 172:253-261.
86. Hermonat P (1991): Enhibition of H Ras expression by the adeno associated virus rep 78 transformation suppressor gene product. Cancer Res 51:3373-3377.
87. Hermonat P (1992): Inhibition of bovine papillomavirus plasmid DNA replication by adeno-associated virus. Virology 189:329-333.
88. Hermonat P (1994): Adeno associated virus inhibits human papillomavirus type 16: a viral interaction implicated in cervical cancer. Cancer Res 54:2278-2281.
89. Herschlag D, Cech T (1990): Catalysis of RNA cleavage by the tetrahymena thermophila ribozyme. I. Kinetic description of the reaction of an RNA substrate complementary to the active site. Biochemistry 29:10159-10171.
90. Hoke G, Draper K, Freier S, Gonzalez C, Driver V, Zounes M, Ecker D (1991): Effects of phosphorothioate capping on antisense oligonucleotide stability, hybridization and antiviral efficacy versus herpes simplex virus infection. NAR 19:5743-5748.
91. Homann M, Tzortzakaki S, Rittner K, Sczakiel G, Tabler M (1993): Incorporation of the catalytic domain of a hammerhead ribozyme into antisense RNA enhances its inhibitory on the replication of human immunodeficiency virus type 1. NAR 21:2809-2814.
92. Horwitz M (1990): Adenovirus and their replication. In: Fields B, Knipe D (eds): Virology 2nd ed. Raven: New York: 1679-1721.
93. Hutchins C, Rathjen P, Forster A, Symons R (1986): Self-cleavage of plus and minus RNA transcripts of avocado sunblotch viroid. NAR 14:3627-3640.
94. Im D, Muzyczka N (1989): Factors that bind to adeno associated virus terminal repeats. J Virol 63:3095-3104.
95. Imperiale M, Kao H, Feldman L, Nevins J, Strickland S (1984): Common control of the heat shock gene and early adenovirus gene: evidence for a cellular E1 A-like activity. Mol Cell Biol 4:867-874.
96. Izant J, Weintraub H (1984): Inhibition of thymidine kinase gene expression by antisense RNA: a molecular approach to genetic analysis. Cell 36:1007-1015.
97. Jaaskelainen I, Monkkonen J, Urtti A (1994): Oligonucleotide-cationic liposome interactions. A physicochemical study. Biochim Biophys Acta 1195:115-123.
98. Juliano R, Akhtar S (1992): Liposomes as a drug delivery system for antisense oligonucleotides. Antisense Res Dev 2:165-176.
99. Kaplitt M, Leone P, Samulski R, Xiao X, Pfaff D, O'Malley K, During M (1994): Long-term gene expression and phenotypic correction using adeno associated virus vectors in the mammalian brain. Nature Genet 8:148-154.
100. Kay M, Rothenberg S, Landen C, Bellinger D, Leland F, Toman C, Finegold M, Thompson A, Read M, Brinkhous K, Woo S (1993): In vivo gene therapy of hemophilia B: sustained partial correction in factor IX-deficient dogs. Science 262:117-119.
101. Kazakov S, Altman S (1991): Site-specific cleavage by metal ion cofactors and inhibitors of ml RNA, the catalytic subunit of RNaseP from Escherichia coli. Proc Natl Acad Sci USA 88:9193-9197.
102. Keese P, Symons R (1987): "Viroids and Viroid-Like Pathogens" Semancik JS (ed): Boca Raton, FL: CRC Press, pp 1-47.
103. Kennedy M, Donehower R, Sartorius S, Chen T, Rowinsky E (1993): Sequences of taxol and cyclophosphamide: a phase I and pharmacologic study in doxorubicin resistant metastatic breast cancer. Proc Am Soc Clin Oncol 12:459.
104. Kim S, Cech T (1987): Three-dimensional model of the active site of the self-splicing rRNA precursor of tetrahymena. Proc Natl Acad Sci USA 84:8788-8792.
105. Klibanov A, Maruyama K, Beckerley A, Torchilin V, Huang L (1991): Activity of amphipathic poly(ethylene glycol) 5000 to prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposome binding to target. Biochim Biophys Acta 1062:142-148.
106. Kole R, Shukla R, Akhtar S (1991): Pre-mRNA splicing as a target for antisense oligonucleotides. Adv Drug Del Rev 6:271-286.
107. Kotin R, Siniscalco M, Samulski R, Zhu X, Hunter L, Laughlin C, McLaughlin S, Muzyczka N, Rocchi M, Berns K (1990): Site-specific integration by adeno associated virus. Proc Natl Acad USA 87:2211-2215.
108. Kotin R, Menninger J, Ward D, Berns K (1991): Mapping and direct visualization of a region specific viral DNA integration site on chromosome 19q13qter. Genomics 10:831-834.
109. Kotin R, Linden R, Berns K (1992): Characterization of a preferred site on human chromosome 19q for integration of adeno-associated virus DNA by non-omologous recombination. EMBO J 11:5071-5078.
110. Kotin R (1994): Review: prospects for the use of adeno associated virus as a vector for human gene therapy. Hum Gene Ther 5:793-801.
111. Kozarsky K, McKinley D, Austin L, Raper S, Stratford-Perricaudet L, Wilson J (1994): In vivo correction of low-density lipoprotein receptor deficiency in the wantanabe heritable hyperlipodemic rabbit with recombinant adenoviruses. J Bio Chem 269:13695-13702.
112. Kulka M, Smith C, Aurelian L, Fishelevich R, Meade K, Miller P, Tso P (1989): Site specificity of the inhibitory effects of oligo (nucleoside methylphosphonates) complementary to the acceptor splice junction of herpes simplex virus type 1 immediate early mRNA Proc Natl Acad Sci USA 86:6868-6872.
113. Labow M, Hermonat P, Berns K (1986): Positive and negative autoregulation of the adeno-associated virus type 2 genome. J Virol 10:251-258.
114. Laughlin C, Tratschin J, Coon H, Carter B (1983): Cloning of infectious adeno-associated virus genomes in bacterial plasmids. Gene 23:65-73.
115. Lebkowski J, McNally M, Okarma T, Lerch L (1988): Adeno-associated virus: a vector system for efficient introduction and integration of DNA into a variety of mammalian cell types. Mol Cell Biol 8:3988-3996.
116. Leder P, Nirenberg M (1964): RNA code words and protein synthesis nucleotide sequence of a valine RNA code word. Proc Natl Acad Sci USA 52:420-427.
117. Ledley F, Brody B, Kozinetz C, Mize S (1992): The challenge of follow up for clinical trials of somatic gene therapy. Hum Gene Ther 3:657-663.
118. LeFebvre R, Berns K (1984): Unique events in parvo-virus replication. Microbiol Sci 1:163-167.
119. LeGal G, LeSal G, Robert J, Berrand S, et al. (1993): An adenovirus vector for gene transfer into neurons and glia in the brain. Science 259:988.
120. Legendre J, Szoka F (1992): Delivery of plasmid DNA into mammalian cell lines using pH-sensitive liposomes: comparison with cationic liposomes. Pharm Res 9:1235-1242.
121. Leib D, Coen, D, Bogard C, Hicks K, Yager D, Knope D, Tyler R, Schaffer P (1989): Immediate early regulatory gene mutants define different stages in the establishment and reactivation of herpes simplex virus latency. J Virol 63:759-768.
122. Lemarchand P, Jones M, Yamada I, Crystal R (1993): In vivo gene transfer and expression in normal uninjured blood vessels using replication deficient recombinant adenovirus vector. Circ Res 72:1132-1138.
123. Leonetti J, Mechti N, Degols G, Gagnor C, LeBleu B (1991): Intracellular distribution of microinjected antisense oligonucleotides. Natl Acad Sci USA 88:2702-2706.
124. L'Huillier P, Davis S, Bellamy A (1992): Cytoplasmic delivery of ribozymes leads to efficient reduction in α-lactal-bumin mRNA levels in C1271 mouse cells. EMBO J 11:4411-4418.
125. Li Q, Kay M, Finegold M, Stratford-Perricaudet L, Woo S (1993): Assessment of recombinant adenoviral vectors for hepatic gene therapy. Hum Gene Ther 4:403-409.
126. Loke S, Stein C, Zhang X, Mori K, Nakanishi M, Subasinghe B, Cohen J, Necker I (1989): Characterization of oligonucleotide transport into living cells. Proc Natl Acad Sci USA 86:3474-3478.
127. Loyter A, Gitman A, Chejanovsky N, Nussbaum O (1986): Fusion-mediated microinjection of macromolecules into living cultured cells by "targeted" Sendai virus envelopes. In Celis J, Graessmann A, Loyter A (eds): Microinjection and Organelle Transplantation Techniques. London: Academic Press, pp 179-197.
128. Loyter A, Citovsky V, Ballas, N (1991): "Membrane Fusion." Wilschut J, Hoekstra D (eds): New York: Marcel Dekker, pp 731-749.
129. Lynch C, Clowes M, Osborne W, Clowes A, Miller D (1992): Long-term expression of human adenosine deaminase in vascular smooth muscle cells of rats: a model for gene therapy. Proc Natl Acad Sci USA 89:1138-1142.
130. Markowitz D, Goff S, Bank A (1988a): A safe packaging line for gene transfer: separating viral genes on two different plasmids. J Virol 62:1120-1124.
131. Markowitz D, Goff S, Bank A (1988b): Construction and use of a safe and efficient amphotropic packaging cell line. Virology 167:400-406.
132. Markwell M, Portner A, Schwartz A (1985): An alternative route of infection for viruses: entry by means of the adialoglycoprotein receptor of the Sendai virus mutant lacking its attachment protein. Proc Natl Acad Sci USA 82:978-982.
133. Martinez O, Kimura J, Henry C, Wofsy L (1986): Converting Sendai virus into a specific fusogen whose cell target can be selected. Exp Cell Res 166:180-190.
134. Mashhour B, Couton D, Perricaudet M, Briand P (1994): In vivo adenovirus-mediated gene transfer into ocular tissues. Gene Ther 1:122-126.
135. Mastrangeli A, Daniel C, Rosenfeld M, Stratford L, Perricaudet M, Pavirani A, Lecocy J, Crystal R (1993): Diversity of airway epithelial cell targets for in vivo recombinant adenovirus mediated gene transfer. J Clin In vest 91:225-234.
136. Matsukura M, Shinozuka K, Zon G, Mitsuya H, Reitz M, Chen J, Broder S (1987): Phosphorothioate analogs of oligodeoxynucleotides: inhibitors of replication and cytopathic effects of human immunodeficiency virus. Proc Natl Acad Sci USA 84:7706-7710.
137. McLachlin J, Eglitis M, Ueda K, Kantoff P, Pastan I, Anderson W, Gotteman M (1990a): Expression of a human complementary DNA for the multidrug resistance gene in murine hematooietic precursor cells with the use of retroviral gene transfer. J Natl Cancer Inst 82:1260-1263.
138. McLachlin J, Cornetta K, Eglitis M, Anderson W (1990b): Retroviral-mediated gene transfer (review). Prog Nucl Acad Res Mol Biol 38:91-135.
139. McLaughlin S, Collis P, Hermonat P, Muzyczka N (1988): Adeno associated virus general transduction vectors: analysis of proviral structure. J Virol 62:1963-1973.
140. McManaway M, Neckers L, Loke S, Al-Nasser A, Redner R, Shiramizu B, Goldschmidts W, Huber B, Bhatia K, Magrath L (1990): Tumour-specific inhibition of lymphoma growth by an antisense oligodeoxynucleotide. Lancet 335:808-811.
141. Michael S, Huang C, Romer M, Wagner E, Hu P, Curiel D (1993): Binding-incompetent adenovirus facilitates molecular conjugate-mediated gene transfer by the receptor-mediated endocytosis pathway. J. Biol. Chem 268:6866-6869.
142. Mickisch G, Schroeder F (1994): From laboratory expertise to clinical practice: multidrug resistance-based gene therapy becomes available for urologists. World J Urol 12:104-111.
143. Mickisch G, Aksentijevich I, Schoenlein P, Goldstein L, Galski I, Stanle C, Sachs D, Pasten I, Gottesman M (1992): Transplantation of bone marrow cells from transgenic mice expressing the human MDR1 gene results in long-term protection against the myelo-suppressive effect of chemotherapy in mice. Blood 79:1087-1093.
144. Mickisch G, Merlino H, Galski M, Gottesman M, Pastan I (1991a): Transgenic mice that express the human multidrug resistance gene in bone marrow enable a rapid identification of agents that reverse drug resistance. Proc Natl Acad Sci USA 88:547-551.
145. Mickisch G, Lieh T, Merlino G, Gottesman M, Pastan I (1991b): Chemotherapy and chemosensitization of transgenic mice which express the human multidrug resistance gene in bone marrow: efficacy, potency and toxicity. Cancer Res 51:5417-5424.
146. Miller A, Buttimore C (1986): Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. Mol Cell Biol 6:2895-2902.
147. Miller A (1990): Retrovirus packaging cells. Hum Gene Ther 1:5-14.
148. Miller A (1992a): Human gene therapy comes of age. Nature 357:455-460.
149. Miller A (1992b): Retroviral vectors. Curr Top Microbiol Immunol 158: 1-24.
150. Mittal S, McDermott M, Johnson D, Prevec L, Graham F (1993): Monitoring foreign gene expression by a human adenovirus-based vector using the firefly luciferase gene as a reporter. Virus Res 28:67-90.
151. Morgenstern J, Land H (1990): Advanced mammalian gene transfer: high titer retroviral vectors with multiple drug selection markers and complementary helper-free packaging cell line. NAR 18:3587-3596.
152. Morvan F, Porumb A, Degols G, LeFebure I, Pompon A, Sproat B, Rayner B, Malay C, LeBleu B, Imbach J (1993): Comparative evaluation of seven ligonucleotide analogues as potential antisense agents. J Med Chem 36:280-287.
153. Mulligan R (1993): The basic science of gene therapy. Science 260:926-932.
154. Muzyczka N (1992): Use of adeno associated virus for mammalian cells. Curr Top Microbiol Immunol 158:97-129.
155. Nabel E, Plautz G, Boyce F, Stanley J (1989): Recombinant gene expression in vivo within endothelial cells of the arterial wall 244:1342-1344.
156. Nabel G, Nabel E, Yang Z, Fox B, Plautz G, Gao X, Huang L, Shu S, Gordon D, Chang A (1993): Direct gene transfer with DNA liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci USA 90:11307-11311.
157. Neckers L, Whitesell L, Rosolen A, Geselowitz D (1992): Antisense inhibition of oncogene expression. Crit Rev Oncogen 3:175-231.
158. Palestine A, Cantrell H, Luckei A (1994): Intravitreal treatment of CMV retinitis with an antisense oligonucleotide ISIS 2922. Tenth International Conference on AIDS, Yokohama, Japan, August 7-12. Abstract.
159. Paria B, Dey S, Andrews G (1992): Antisense c-myc affects on preimplantation mouse embryo development. Proc Natl Acad Sci USA 89:10051-10055.
160. Peterhans E, Baechi T, Yewdell J (1988): Evidence for different receptor sites in mouse spleen cells for the Sendai virus hemagglutinin-neuraminidase (HN) and fusion (F) glycoproteins. Virology 128:366-376.
161. Piazza F, Johnson A, Darnell M, Porter D, Hemming V, Prince G (1993): Bovine respiratory syncytial virus protects cotton rats against human respiratory syncytial virus infection. J Virol 67:1503-1510.
162. Plautz G, Nabel E, Nabel G (1991): Introduction of vascular smooth muscle cells expressing recombinant genes in vivo. Circulation 83:578-583.
163. Pyle A (1993): Ribozymes: a distinct class of metalloenzymes. Science 261:709-714.
164. Quantin B, Perricaudet L, Tajbakhsh S, Mandel J (1992): Adenovirus as an expression vector in muscle cells in vivo. Proc Natl Acad Sci USA 89:2581-2584.
165. Ragot T, Vincent N, Chafey P, Vigne E, Gilgenkrantz H, Couton D, Cartoud J, Briand P, Kaplan J, Perricaudet M (1993): Efficient adenovirus-mediated transfer of a human mini dystrophin gene to skeletal muscle of mdx mice. Nature 361:647-650.
166. Roizman B, Batterson W (1985): "Virology." Fields B (ed): New York: Raven, pp 497-526.
167. Rosenfeld M, Siegfried W, Yoshimura K, Yoneyama K, Fukayama M, Stier L, Paakko P, Gilardi P, Statford L, Perricaudet M (1992a): Adenoviral-mediated transfer of a recombinant α1-antitrypsin gene to the lung epithelium in vivo. Science 252:431-434.
168. Rosenfeld M, Yoshimura K, Trapnell B, Yoneyama K, Rosenthal E, Dalemars W, Fukayama M, Bargon J, Stier L, Perricaudet M (1992b): In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell 68:143-155.
169. Ruffner D, Dahm S, Uhlenbeck O (1989): Studies on the hammerhead RNA self-cleaving domain. Gene 82: 31-42.
170. Russell S, Hawkins R, Winter G (1993): Retroviral vectors displaying functional antibody fragments. NAR 21:1081-1085.
171. Salmons B, Gunzburg W (1993): Targeting of retroviral vectors for gene therapy. Hum Gene Ther 4:129-141.
172. Sambrook J, Fritsch E, Maniatis T (1989): "Molecular Cloning: A Laboratory Manual." New York: Cold Springs Harbor.
173. Sami I, Piazza F, Johnson S, Darnell M, Ottolini M, Hemming V, Prince G (1995): Systemic immunoprophlaxis of nasal respiratory syncytial virus infection in cotton rats. J Infect Dis 171:440-443.
174. Samulski R, Chang L, Shen K (1989): Helper free stocks of recombinant adeno associated viruses: Normal integration does not require viral gene expression. J Virol 63:3822-3828.
175. Samulski R, Zhu X, Xaio X, Brook J, Housman D, Epstein N, Hunter L (1991): Targeted integration of adeno-associated virus (AAV) into human chromosome 19. EMBO J 10:3941-3950.
176. Sanghvi Y, Hoke G, Freier S, Zounes M, Genzalez C, Cummins L, Sasmor H, Cook P (1993): Antisense oligodeoxynucleotides: synthesis, biophysical, and biological evaluation of oligodeoxynucleotides containing modified pyrimidines. NAR 21:3197-3203.
177. Sarver N, Cantin E, Chang P, Zaia J, Ladne P, Stephens D, Rossi J (1990): Ribozymes as potential anti-HIV-1 therapeutic agents. Science 247:1222-1225.
178. Saxena S, Ackerman E (1990): Ribozymes correctly cleave a model substrate and endogenous RNA in vivo. J Bio Chem 265:17106-17109.
179. Scanlon K, Jiao L, Funato T, Wang W, Tone T, Rossi J, Kashani-Sabet M (1991): Ribozyme-mediated cleavage of c-fos mRNA reduces gene expression of DNA synthesis enzymes and metallothionein. Proc Natl Acad Sci USA 88:10591-10595.
180. Scarpa M, Cournoyer D, Muzny D, Moore K, Belmont J, Caskey C (1991): Characterization of recombinant helper retroviruses form Moloney-based vectors
181. Scherphof G (1986): "Lipids and Membranes: Past Previous and Future." Opden Kamp JAF, Roelofsen B, Woo KWA (ed): Amsterdam: Elsevier, pp 113-136.
182. Setoguchi Y, Danel C, Crystal R (1994): Stimulation and erythroporesis by in vivo gene therapy: physiologic consequences of transfer of the human erythropoietin gene to experimental animals using an adenovirus vector. Blood 84:2946-2953.
183. Sioud M, Drlica K (1991): Prevention of human immunodeficiency virus type 1 integrase expression in Escherichia coli by a ribozyme. Proc Natl Acad Sci USA 88:7303-7307.
184. Snyder E, Taylor R, Wolfe J (1995): Neural progenitor cell engraftment corrects lysosomal storage throughout the MPS VII mouse brain. Nature 374:367-370.
185. Snyder R, Im D, Ni T, Xiao X, Samulski R, Muzyczka N (1993): Features of the adeno associated virus origin involved in substrate recognition by the viral rep protein. J Virol 67:6096-6104.
186. Spergel J, Hsu W, Akira S, Thimmappaya B, Kishinoto T, Chen-Kiang S (1992): NF-IL6, a member of the C.EBP family, regulates E1A-responsive promoters in the absence of E1a. J Virol 66:1021-1030.
187. Spitzer F, Eckstein F (1988): Inhibition of deoxyribonucleases by phosphorothioate groups in oligodexoribonucleotides. NAR 16:11691-11704.
188. Stein CA, Cheng, YC (1993): Antisense oligonucleotides as therapeutic agents -is the bullet really magical? Science 261:1004-1012.
189. Steinecke P, Herget T, Schreier P (1992): Expression of a chimeric ribozyme gene results in endonucleolytic cleavage of target m/RNA and a concomitant reduction of gene expression in vivo. EMBO J 11:1525-1530.
190. Szoka F (1986): The cellular availability of liposome-encapsulated agents: consequences for drug therapy. In Yagi K (ed): "Medical Application of Liposomes." Tokyo: Japan Scientific Societies Press, pp 21-30.
191. Temin H (1989): Retrovirus vectors: promise and reality (review). Science 246:983.
192. Tepper R, Pattengale P, Leder P (1989): Murine interleukin-4 displays potent antitumor activity in vivo. Cell 57:503-512.
193. Tepper R, Mule J (1994): Experimental and clinical studies of cytokine gene modified tumor cells. Hum Gene Ther 6:153-164.
194. Tomita N, Higati J, Ogihara T, Konodo T, Kaneda Y ( 1994): A novel gene transfer technique mediated by HVJ (Sendai virus), nuclear protein, and liposomes. Cancer Detec Prev 18:485-491.
195. Thrasher J, Crawford E (1993): Current management of invasive and metastatic transitional cell carcinoma of the bladder. J Urol 149:957-972.
196. Tidd D, Warenius H (1989): Partial protection of oncogene, antisense oligodeoxynucleotides against serum nuclease degradation using terminal methyl phosphonate groups. Br J Cancer 60:343-350.
197. Tomita N, Higaki J, Ogihara T, Kondo T, Kaned Y (1994): A novel gene transfer technique mediated by HVJ (Sendai virus), nuclear protein, and liposomes. Cancer Detec Prev 18:485-491.
198. Trastchin J, Tal J, Carter B (1986): Negative and positive regulation in trans of gene expression from adeno associated virus vectors in mammalian cells by viral rep gene product. Mol Cell Biol 6:2884-2894.
199. Trempe J, Carter B (1988): Regulation of adeno associated virus gene expression in 293 cells: control of mRNA abundance and translation. J Virol 62:68-74.
200. Tsuchihashi Z, Khosia M, Herschlag D (1993): Protein enhancement of hammerhead ribozyme catalysis. Science 262:99-102.
201. Uhlenbeck O (1987): A small catalytic oligoribonucleotide. Nature 328:596-600.
202. Vita V, Hubbard S, Young R, Long D (1988): High-dose consolidation therapy with autologous stem-cell rescue in stage IV breast cancer: follow-up report. J Clin Oncol 10:1743-1747.
203. Vogelzang N, Lestingi T, Sudakoff G, Gradjian S (1994): Phase I study of immunotherapy of metastatic renal cell carcinoma by direct gene transfer into metastatic lesions. Hum Gene Ther 5:1368-1370.
204. Wagner RW (1994): Gene inhibition using antisense oligodeoxynucleotides. Nature 372:333-335
205. Wagner E, Zatloukal K, Cotten M, Kirlappos H, Mechtler K, Curiel D, Birnstiel M (1992): Coupling of adenovirus to transferrin-polylysine DNA complexes greatly enhances receptor mediated gene delivery and expression of transfected genes. Proc Natl Acad Sci USA 89:6099-6103.
206. Wagner E, Plank C, Zatloukal K, Gotten M, Birnstiel M (1992): Influenza virus hemagglutinin HA-2 N terminal fusogenic peptides augment gene transfer by transferrin-polylysine-DNA complexes: toward a synthetic virus like gene transfer vehicle. Proc Natl Acad Sci USA 89:7934-7938.
207. Wang C, Huang L (1987): Plasmid DNA adsorbed to pH sensitive liposomes efficiently transforms target cells. Biochem Biophys Res Comm 147:980-985.
208. Watson J, Berek J, Martinez-Maza O (1993): Growth inhibition of ovarian cancer cells induced by antisense IL-6 oligonucleotides. Gynecol Oncol 49:8-15.
209. Weiden M, Ginsberg H (1994): Deletion of the E4 region of the genome produces adenovirus DNA concatemers. Proc Natl Acad Sci USA 91:153-157.
210. Wickstrom R (1986): Oligodeoxynucleotide stability in subcellular extracts and culture media. J Biochem Biophys Meth 13:97-102.
211. Wu G, Wu C (1987): Receptor mediated in vitro gene transformation by a soluable dna carrier system. J Biol Chem 262:4429-4432.
212. Wu G, Wu C (1992): Specific inhibition of hepatitis B viral gene expression in vitro by targeted antisense oligonucleotides. J Biol Chem 267:12436-12439.
213. Xing Y, Johnson C, Dobner P, Lawrence J (1993): Higher level organization of individual gene transcription and RNA splicing. Science 259:1326-1330.
214. Yang Y, Nunes F, Berencsi K, Furth E, Gonczol E, Wilson J (1994): Cellular immunity to viral antigens limits Eldeleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 91:4407-4411.
215. Yang Y, Li Q, Ertl H, Wilson J (1995): Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adeno-viruses. J Virol 69:2004-2015.
216. Yei S, Mittereder N, Tang K, O'Sullivan C, Trapnell B (1994): Adenovirus-mediated gene transfer for cystic fibrosis: quantitative evaluation of repeated in vivo vector administration to the lung. Gene Ther 1:192-200.
217. Zabner J, Couture L, Smith A, Welsh M (1994): Correction of camp stimulated fluid secretion in cystic fibrosis airway epithelial: efficiency of adenoviral mediated gene transfer in vitro. Hum Gene Ther 5:585-593.
218. Zon G (1988): Oligonucleotide analogues as potential chemotherapeutic agents. Pharmacol Res 5:539-549.